Clinical trials: Linear Growth
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Nonsmall Cell
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.
- Trial name
- NCT06319950
- Testing
- Furmonertinib, Osimertinib
- Volunteers
- 255 people
- Sponsor
- Taizhou Hospital
Intrahepatic Cholangiocarcinoma
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
This is a single-arm, open-label, multi-center Phase II clinical trial intended to observe and evaluate the efficacy and safety of famitinib malate in treating iCCA(Intrahepatic Cholangiocarcinoma ) patients with FGFR2 genetic…
- Trial name
- NCT04479904
- Testing
- Famitinib
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Stunting, Birth Weight
Aflatoxin Birth Cohort Study Nepal (AflaCohort)
The study focuses on the causal relationship between mycotoxin exposure (particularly aflatoxin B1), birth outcomes, and height for age among young children in Nepal.
- Conditions
- Stunting, Birth Weight, Birth Length, Height for Age
- Trial name
- AflaCohort (NCT03312049)
- Volunteers
- 1,675 people, healthy volunteers welcome
- Sponsor
- Tufts University
Skin Health, Collagen Supplementation
IMPACT OF SUPPLEMENTATION WITH LOW MOLECULAR WEIGHT HYDROLYZED COLLAGEN AND VERISOL ON THE EXPRESSION OF LINES, SKIN QUALITY, AND LEVELS OF KLOTHO, VEGF, AND TGF-BETA IN THE EYE REGION
Skin is the largest organ of the human body and performs various vital functions, including protection against external agents, regulation of body temperature, and sensory perception.
- Conditions
- Skin Health, Collagen Supplementation, Growth Factors
- Trial name
- NCT06971029
- Testing
- Supplementation with Verisol®, Supplementation with Peptech® 2.5G, Supplementation with Peptech® 10.0G
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Metastatic Breast Cancer
2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
First-line treatment of patients with locally recurrent or metastatic, HER2-negative breast cancer who have not received prior chemotherapy for locally recurrent or metastatic disease.
- Trial name
- TURANDOT (NCT00600340)
- Testing
- Bevacizumab and Paclitaxel, Bevacizumab and Capecitabine
- Where
- 55 sites in Austria, Bosnia and Herzegovina and 10 more
- Volunteers
- 564 people
- Sponsor
- Central European Cooperative Oncology Group
NSCLC
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment
1. Detection EGFR mutation of cancer cells from malignant pleural effusion. 2. Established the cancer cell lines with without EGFR mutation from malignant pleural effusion.
- Trial name
- EGFR (NCT00752076)
- Testing
- cancer cell lines establishment
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Skin Diseases, Carcinoma, Squamous Cell
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
The purpose of this study is to determine whether cetuximab is effective in the treatment of locally advanced or metastatic squamous cell carcinoma of the skin expressing EGFR.
- Trial name
- CTXSCC (NCT00240682)
- Testing
- cetuximab
- Where
- 14 sites in France
- Volunteers
- 37 people
- Sponsor
- Centre Hospitalier of Chartres
HER2-positive Gastric Cancer
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma
- Trial name
- NCT06492317
- Testing
- Disitamab Vedotin, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University